Stem Pharm has been Awarded a $1.5M Phase II NIH SBIR Grant from NINDS

Stem Pharm has been awarded a Phase II NIH SBIR grant (R44NS102088; PI: Dr. Lebakken) through the National Institute Of Neurological Disorders And Stroke (NINDS) entitled: Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine. This effort will use Stem Pharm’s hydrogel coatings for efficient differentiation and maturation of iPSC-derived neurons that can be used for modeling neurodevelopmental disorders and enabling new precision therapies.